Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.

Abstract

The recombinant CD3 immunotoxin, A-dmDT(390)-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3epsilon monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

• Authors: A E Frankel, S L Zuckero, A A Mankin, M Grable, K Mitchell, Y J Lee, D M Neville, J H Woo
• Journal: Current drug targets (Curr Drug Targets) Vol. 10 Issue 2 Pg. 104-9 (Feb 2009) ISSN: 1873-5592 [Electronic] United Arab Emirates
• PMID: 19199905 (Publication Type: Journal Article, Review)

Chemical References

• CD3 Complex
• Diphtheria Toxin
• Immunotoxins
• Recombinant Fusion Proteins

Topics

• Aged
• CD3 Complex (immunology)
• Diphtheria Toxin (adverse effects, therapeutic use)
• Drug Delivery Systems
• Female
• Humans
• Immunotoxins (adverse effects, therapeutic use)
• Lymphoma, T-Cell (therapy)
• Male
• Middle Aged
• Recombinant Fusion Proteins (adverse effects, therapeutic use)
• Skin Neoplasms (therapy)